Opendata, web and dolomites

LITMUS SIGNED

Liver Investigation: Testing Marker Utility in Steatohepatitis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "LITMUS" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITY OF NEWCASTLE UPON TYNE 

Organization address
address: KINGS GATE
city: NEWCASTLE UPON TYNE
postcode: NE1 7RU
website: http://www.ncl.ac.uk/

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 32˙472˙404 €
 EC max contribution 15˙797˙881 € (49%)
 Programme 1. H2020-EU.3.1.7.13. (Other)
 Code Call H2020-JTI-IMI2-2016-09-two-stage
 Funding Scheme /IMI2-RIA
 Starting year 2017
 Duration (year-month-day) from 2017-11-01   to  2022-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITY OF NEWCASTLE UPON TYNE UK (NEWCASTLE UPON TYNE) coordinator 2˙764˙662.00
2    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD UK (OXFORD) participant 1˙872˙000.00
3    NORDIC BIOSCIENCE COMPOUND DEVELOPMENT A/S DK (Helev) participant 1˙427˙093.00
4    Academisch Medisch Centrum bij de Universiteit van Amsterdam NL (AMSTERDAM) participant 1˙180˙910.00
5    UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZ DE (Mainz) participant 1˙073˙015.00
6    INST CARDIOMETABOLISME NUTRITION ICAN FR (PARIS) participant 1˙000˙750.00
7    THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE UK (CAMBRIDGE) participant 638˙130.00
8    SERVICIO ANDALUZ DE SALUD ES (SEVILLA) participant 601˙250.00
9    UNIVERSITAET BERN CH (BERN) participant 435˙000.00
10    LUXEMBOURG INSTITUTE OF HEALTH LU (LUXEMBOURG) participant 434˙034.00
11    UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT DE (WURZBURG) participant 406˙206.00
12    ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS ES (DERIO VIZCAYA) participant 403˙017.00
13    UNIVERSITA DEGLI STUDI DI TORINO IT (TORINO) participant 345˙160.00
14    IXSCIENT LIMITED UK (TWICKENHAM MIDDLESEX) participant 344˙375.00
15    OREBRO UNIVERSITY SE (OREBRO) participant 312˙500.00
16    UNIVERSITAIR MEDISCH CENTRUM UTRECHT NL (UTRECHT) participant 273˙328.00
17    PERSPECTUM DIAGNOSTICS LTD UK (OXFORD) participant 250˙000.00
18    UNIVERSITAETSKLINIKUM AACHEN DE (AACHEN) participant 248˙076.00
19    ANTAROS MEDICAL AB SE (MOLNDAL) participant 231˙275.00
20    HELSINGIN YLIOPISTO FI (HELSINGIN YLIOPISTO) participant 202˙500.00
21    ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS FR (PARIS) participant 170˙000.00
22    UNIVERSITAIR ZIEKENHUIS ANTWERPEN BE (EDEGEM) participant 167˙100.00
23    UNIVERSITE D'ANGERS FR (ANGERS CEDEX 01) participant 122˙500.00
24    ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON EL (ATHINA) participant 118˙350.00
25    THE UNIVERSITY OF NOTTINGHAM UK (NOTTINGHAM) participant 118˙115.00
26    UNIVERSITA DEGLI STUDI DI PALERMO IT (PALERMO) participant 105˙081.00
27    UNIVERSITA DEGLI STUDI DI MILANO IT (MILANO) participant 80˙722.00
28    UNIVERSITA CATTOLICA DEL SACRO CUORE IT (MILANO) participant 80˙653.00
29    LINKOPINGS UNIVERSITET SE (LINKOPING) participant 79˙600.00
30    FACULDADE DE MEDICINA DA UNIVERSIDADE DE LISBOA PT (LISBOA) participant 78˙487.00
31    EUROPEAN ASSOCIATION FOR THE STUDYOF THE LIVER CH (ZURICH) participant 61˙680.00
32    THE UNIVERSITY OF BIRMINGHAM UK (BIRMINGHAM) participant 61˙263.00
33    Faculdade de Farmácia da Universidade de Lisboa PT (Lisboa) participant 56˙968.00
34    MEDIZINISCHE UNIVERSITAET WIEN AT (WIEN) participant 54˙075.00
35    Boehriger Ingelheim International GmbH DE (INGELHEIM) participant 0.00
36    Eli Lilly and Company Ltd UK (Basingstoke) participant 0.00
37    ELLEGAARD GOTTINGEN MINIPIGS AS DK (DALMOSE) participant 0.00
38    EXALENZ BIOSCIENCE LTD IL (MODIIN) participant 0.00
39    GENFIT FR (LOOS) participant 0.00
40    INTERCEPT PHARMA EUROPE LTD UK (BRISTOL) participant 0.00
41    NOVARTIS PHARMA AG CH (BASEL) participant 0.00
42    NOVO NORDISK A/S DK (BAGSVAERD) participant 0.00
43    ONE WAY LIVER SL ES (DERIO BIZKAIA) participant 0.00
44    Pfizer Ltd UK (SANDWICH) participant 0.00
45    SANOFI-AVENTIS DEUTSCHLAND GMBH DE (FRANKFURT AM MAIN) participant 0.00
46    SOMALOGIC INC US (BOULDER COLORADO) participant 0.00
47    Takeda Development Centre Europe Ltd. UK (LONDON) participant 0.00

Mappa

 Project objective

Strongly associated with the epidemics of obesity and type 2 diabetes that are testing healthcare systems worldwide, Non-Alcoholic Fatty Liver Disease (NAFLD) is an increasingly common cause of advanced liver disease that is characterized by substantial inter-patient variability in severity and rate of progression. It is currently assessed by liver biopsy, an invasive, costly and risky procedure. The lack of noninvasive biomarkers has hampered patient care and impeded drug development by complicating conduct of clinical trials.The overarching aim of LITMUS is to develop, robustly validate and advance towards regulatory qualification biomarkers that diagnose, risk stratify and/or monitor NAFLD/NASH progression and fibrosis stage. This will be achieved through a goal-oriented, tri-partite collaboration delivering a definitive and impartial evaluation platform for biomarkers, bringing together: (i) End-users of biomarker technologies (clinicians with expertise in NAFLD and the pharmaceutical industry)? (ii) Independent academics with expertise in the evaluation of medical test/biomarker performance? and (iii) Biomarker researchers and developers (academic or commercial).

LITMUS has the demonstrable capability to fulfil the IMI call remit. Built upon foundations laid by the EU-funded FLIP/EPoS projects and long-established, successful scientific collaborations amongst many of Europe’s leading clinical-academic centres, LITMUS is at a unique advantage due to its existing large-scale patient cohorts, bioresources and multi-omics datasets. Consortium members are internationally recognised experts with substantial relevant expertise supporting the program’s clear focus on biomarker identification, validation and accelerating EMA/FDA qualification. Thus, LITMUS is powered to provide clarity on biomarker validity for NAFLD at scale and pace: supporting drug development and the targeting of medical care and limited healthcare resources to those at greatest need.

 Work performed, outcomes and results:  advancements report(s) 

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LITMUS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LITMUS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.13.)

EBOVAC1 (2014)

Development of a Prophylactic Ebola Vaccine Using an Heterologous Prime-Boost Regimen

Read More  

eTRANSAFE (2017)

Enhacing TRANslational SAFEty Assessment through Integrative Knowledge Management

Read More  

EBODAC (2014)

Communication strategy and tools for optimizing the impact of Ebola vaccination deployment.

Read More